Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Cycle record

Assessment cycle 2026 Q3 — page 2

Documents ratified in the 2026 Q3 assessment cycle, which ran from 1 July 2026 to 30 September 2026 and was ratified on 18 September 2026.

Documents ratified

554 documents · page 2 of 14

Bibliographic record: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and…

CEI-BR-040Bibliographic record2026-q3

The Lancet 2018

30 Jul 2026
Bibliographic record: Measuring inconsistency in meta-analyses

CEI-BR-041Bibliographic record2026-q3

BMJ 2003

30 Jul 2026
Bibliographic record: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight…

CEI-BR-042Bibliographic record2026-q3

Diabetes Care 2003

30 Jul 2026
Bibliographic record: Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

CEI-BR-043Bibliographic record2026-q3

New England Journal of Medicine 2017

30 Jul 2026
Bibliographic record: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

CEI-BR-044Bibliographic record2026-q3

New England Journal of Medicine 2019

30 Jul 2026
Bibliographic record: ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in…

CEI-BR-045Bibliographic record2026-q3

ICH Harmonised Guideline 2023

30 Jul 2026
Bibliographic record: ICH Q1A(R2) Stability Testing of New Drug Substances and Products

CEI-BR-046Bibliographic record2026-q3

ICH Harmonised Tripartite Guideline 2003

30 Jul 2026
Bibliographic record: ICH Q2(R2) Validation of Analytical Procedures

CEI-BR-047Bibliographic record2026-q3

ICH Harmonised Guideline 2023

30 Jul 2026
Bibliographic record: ICH Q3C(R9) Impurities: Guideline for Residual Solvents

CEI-BR-048Bibliographic record2026-q3

ICH Harmonised Guideline 2024

30 Jul 2026
Bibliographic record: ICH Q6B Specifications: Test Procedures and Acceptance Criteria for…

CEI-BR-049Bibliographic record2026-q3

ICH Harmonised Tripartite Guideline 1999

30 Jul 2026
Bibliographic record: ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration…

CEI-BR-050Bibliographic record2026-q3

ISO/IEC Standard 2017

30 Jul 2026
Bibliographic record: Tirzepatide once weekly for the treatment of obesity

CEI-BR-051Bibliographic record2026-q3

New England Journal of Medicine 2022

30 Jul 2026
Bibliographic record: Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

CEI-BR-052Bibliographic record2026-q3

New England Journal of Medicine 2023

30 Jul 2026
Bibliographic record: Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and…

CEI-BR-053Bibliographic record2026-q3

European Journal of Pharmaceutical Sciences 2017

30 Jul 2026
Bibliographic record: Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a…

CEI-BR-054Bibliographic record2026-q3

Diabetes, Obesity and Metabolism 2023

30 Jul 2026
Bibliographic record: Semaglutide once a week in adults with overweight or obesity, with or without type 2…

CEI-BR-055Bibliographic record2026-q3

The Lancet Diabetes & Endocrinology 2022

30 Jul 2026
Bibliographic record: LC–MS bioanalysis of intact proteins and peptides

CEI-BR-056Bibliographic record2026-q3

Biomedical Chromatography 2020

30 Jul 2026
Bibliographic record: Quality of peptide products obtained from unregulated online suppliers: an analytical…

CEI-BR-057Bibliographic record2026-q3

Journal of Pharmaceutical Sciences 2024

30 Jul 2026
Bibliographic record: Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory…

CEI-BR-058Bibliographic record2026-q3

Advances in Gerontology 2020

30 Jul 2026
Bibliographic record: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1)…

CEI-BR-059Bibliographic record2026-q3

The Lancet 2023

30 Jul 2026
Bibliographic record: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable…

CEI-BR-060Bibliographic record2026-q3

Journal of Medicinal Chemistry 2000

30 Jul 2026
Bibliographic record: Semaglutide in patients with heart failure with preserved ejection fraction and obesity

CEI-BR-061Bibliographic record2026-q3

New England Journal of Medicine 2023

30 Jul 2026
Bibliographic record: Semaglutide in patients with obesity-related heart failure and type 2 diabetes

CEI-BR-062Bibliographic record2026-q3

New England Journal of Medicine 2024

30 Jul 2026
Bibliographic record: Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide

CEI-BR-063Bibliographic record2026-q3

Journal of Medicinal Chemistry 2015

30 Jul 2026
Bibliographic record: Once-weekly cagrilintide for weight management in people with overweight and obesity: a…

CEI-BR-064Bibliographic record2026-q3

The Lancet 2021

30 Jul 2026
Bibliographic record: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces…

CEI-BR-065Bibliographic record2026-q3

Cell Metabolism 2015

30 Jul 2026
Bibliographic record: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised…

CEI-BR-066Bibliographic record2026-q3

The Lancet Diabetes & Endocrinology 2024

30 Jul 2026
Bibliographic record: Semaglutide and cardiovascular outcomes in obesity without diabetes

CEI-BR-067Bibliographic record2026-q3

New England Journal of Medicine 2023

30 Jul 2026
Bibliographic record: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or…

CEI-BR-068Bibliographic record2026-q3

The Lancet 2021

30 Jul 2026
Bibliographic record: Tirzepatide for the treatment of obstructive sleep apnea and obesity

CEI-BR-069Bibliographic record2026-q3

New England Journal of Medicine 2024

30 Jul 2026
Bibliographic record: Stability of protein pharmaceuticals: an update

CEI-BR-070Bibliographic record2026-q3

Pharmaceutical Research 2010

30 Jul 2026
Bibliographic record: HPLC analysis and purification of peptides

CEI-BR-071Bibliographic record2026-q3

Methods in Molecular Biology 2007

30 Jul 2026
Bibliographic record: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

CEI-BR-072Bibliographic record2026-q3

New England Journal of Medicine 2016

30 Jul 2026
Bibliographic record: Liraglutide and cardiovascular outcomes in type 2 diabetes

CEI-BR-073Bibliographic record2026-q3

New England Journal of Medicine 2016

30 Jul 2026
Bibliographic record: Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL): a…

CEI-BR-074Bibliographic record2026-q3

New England Journal of Medicine 2025

30 Jul 2026
Bibliographic record: GLP-1 receptor agonists: reminder of the risk of hypoglycaemia and of use only for…

CEI-BR-075Bibliographic record2026-q3

MHRA Drug Safety Update 2023

30 Jul 2026
Bibliographic record: Falsified Ozempic (semaglutide) pens: patient safety alert

CEI-BR-076Bibliographic record2026-q3

MHRA Safety Alert 2023

30 Jul 2026
Bibliographic record: Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a…

CEI-BR-077Bibliographic record2026-q3

The Lancet Diabetes & Endocrinology 2024

30 Jul 2026
Bibliographic record: Glucagon-like peptide 1 (GLP-1)

CEI-BR-078Bibliographic record2026-q3

Molecular Metabolism 2019

30 Jul 2026
Bibliographic record: GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art

CEI-BR-079Bibliographic record2026-q3

Molecular Metabolism 2021

30 Jul 2026

page 2 of 14

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.